US health spending growth for 2009 at 4% is lowest in five decades

7 January 2011

In 2009, US health care spending grew just 4.0% - a historically low rate of annual increase - to $2,500 billion, or $8,086per person. Despite the slower growth, the share of the gross domestic product devoted to health spending increased to 17.6% in 2009 from 16.6% in 2008, according to a report prepared annually by the Centers for Medicare and Medicaid Services (CMS) Office of the Actuary.

The growth rate of health spending continued to outpace that of the overall economy, which experienced its largest drop since 1938. The recession contributed to slower growth in private health insurance spending and out-of-pocket spending by consumers, as well as a reduction in capital investments by health care providers. The recession also placed increased burdens on households, businesses, and governments, which meant that fewer financial resources were available to pay for health care. Declining federal revenues and strong growth in federal health spending increased the health spending share of total federal revenue from 37.6% in 2008 to 54.2% in 2009.

However, these figures do not reflect the impact of President Barack Obama's landmark health coverage expansion, which did not pass until 2010. The same Medicare office has previously projected the overhaul will lead to a slight increase in total health care spending, even as it extends coverage to nearly all Americans, noted a review by The Associated Press.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical